


PF-06445974

Cat. No.:	HY-119190		
CAS No.:	2055776-17-3		
Molecular Formula:	C ₂₀ H ₁₅ FN ₄ O		
Molecular Weight:	346.36		
Target:	Phosphodiesterase (PDE)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (96.23 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.8872 mL	14.4358 mL	28.8717 mL
	5 mM	0.5774 mL	2.8872 mL	5.7743 mL
	10 mM	0.2887 mL	1.4436 mL	2.8872 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at PDE4B with an IC₅₀ <1 nM. The IC₅₀ values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study^[1].

IC₅₀ & Target

PDE4B	PDE4D	PDE4A	PDE4C
<1 nM (IC ₅₀)	36 nM (IC ₅₀)	4.7 nM (IC ₅₀)	17 nM (IC ₅₀)

In Vitro

PF-06445974 demonstrates minimal off-target activities in broad-spectrum selectivity panels, with only weak μM activities at PDE10 (IC₅₀=2290 nM), PDE5A (IC₅₀=4640 nM) and GABAA (K_i=3850 nM)^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PF-06445974 exhibits high central nervous system (CNS) PET MPO score (4.0). PF-06445974 is a promising radiotracer lead for specific binding assessment. Neuropharmacokinetic study in rats (0.1 mg/kg, IV) confirms high brain permeability with a total brain to plasma ratio of 0.76, corresponding to a free brain to plasma ratio of 0.70^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Twenty-five drug-naive male 129/B6 PDE4D KO mice (25-35 g) ^[1]
Dosage:	10 µg/kg
Administration:	Dosed intravenously at 10 µg/kg in a 5 mL/kg dosing volume
Result:	Showed excellent brain uptake and reached peak concentrations at around 20 minutes.

REFERENCES

[1]. Lei Zhang, et al. The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging. J Med Chem. 2017 Oct 26;60(20):8538-8551.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA